Impact Of Breast Cancer Adjuvant Chemotherapy On The Clinical Observation

OBJECTIVE: Adjuvant chemotherapy for breast cancer influence on menstrual factors, for the protection of ovarian function in patients with chemotherapy to provide evidence.METHODS: 165 cases were collected from May 2005 to May 2009 the First Affiliated Hospital of Guangxi Medical University, breast surgery patients, patients with breast cancer confirmed by pathology in our hospital with systemic adjuvant chemotherapy refers to disease and indication. Aged 25-48 years, mean age was 41.13 years old, the normal treatment period, no other system tumors and diseases, and has not taken within six months of hormone drugs. Observation period as well as in patients with perimenopausal symptoms, analyze the impact of chemotherapy-induced abnormal menstrual factors, in order to reduce the damage of chemotherapy on ovarian function to provide evidence.RESULT: 1.165 cases of breast cancer, chemotherapy, 108 patients (65.45%) amenorrhea, 50 (30.30%) patients had menstrual disorders, 7 (4.24%) cases no significant changes in menstruation. Amenorrhea, 60 cases (55.55%) resumed menstruation, in which 54 patients (50.0%) 2-12 months after stopping the rehabilitation of 6 cases (5.55%) recovery in 13-18 months, 48 patients (44.44% ) up to February 2010 not to resume menstruation, 30 (27.28%) patients had perimenopausal symptoms, mainly hot flashes, sweating, irritability, sexual dissatisfaction and other symptoms. 2. Amenorrhea group began chemotherapy at the age of 30 to 48 years, mean age 40.81±3.89 years, menstrual disorder and began chemotherapy at the age of 26 to 39 years old, mean age 33.90±3.42 years, the rules set period began chemotherapy at the age of 25 37 years old, mean age 30.57±4.93 years. Amenorrhea group began chemotherapy, age greater than normal menstrual disorder group and the group's average age of menstruation, by group t test, p <0.05; menstrual disorder and began chemotherapy in the control group of age and menstrual age of starting chemotherapy, t test, p> 0.05, not significant. 3. CAF program with 123 cases, 78 cases of amenorrhea, amenorrhea rate of 63.4%; with 42 cases of TE programs, there are 30 cases of amenorrhea, amenorrhea rate was 71.4%, two by theχ2 test, p> 0.05, no significant difference. 4. Using CAF programs and TE program and paclitaxel in patients with cumulative cyclophosphamide dose increased, the number of menopause also increased, p<0.05, significant difference. 5. Amenorrhea serum FSH (follicle stimulating hormone, FSH), luteinizing hormone (1uteinizing hormone, LH) levels were significantly higher than patients without amenorrhea, estradiol (estrodio, E2) levels were significantly lower than patients without amenorrhea , p <0.05.CONCHLSIONS: Chemotherapy drugs can cause menstrual changes. The impact of chemotherapy on the period beginning chemotherapy in patients with age, cumulative dose of drugs, nothing to do with chemotherapy. For the protection of ovarian function in patients with chemotherapy drug of choice as far as possible on the ovarian function of small doses of chemotherapy drugs less damage, choose the appropriate ways to protect the patient's reproductive function. Whether the use of chemotherapy in patients with postmenopausal HRT replacement therapy remains controversial. .